Protagonist Therapeutics initiated dosing in the Phase 1 study of PN-10943, an oral, gut-restricted alpha-4-beta-7 integrin antagonist peptide in development for the potential treatment of inflammatory bowel disease. The study is designed to evaluate safety, tolerability, pharmacokinetics and pharmacodynamic parameters of PN-10943. The Phase 1 data will be used to design a Phase 2a study in ulcerative colitis patients expected to begin in 2H19. Primary endpoints for the study are safety and tolerability. Secondary endpoints include evaluation of pharmacokinetic properties and pharmacodynamic parameters of blood receptor occupancy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.